CAN-FITE BIOPHARMA LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.9 ILa | 0.00% |
|
+7.41% | +11.54% |
| 05-12 | Transcript : Can-Fite BioPharma Ltd. - Special Call | |
| 05-09 | Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study | CI |
| Sales 2024 * | 900K 330M 70.76M | Sales 2025 * | 900K 330M 70.76M | Capitalization | 11.79M 4.33B 927M |
|---|---|---|---|---|---|
| Net income 2024 * | -7M -2.57B -550M | Net income 2025 * | -8M -2.94B -629M | EV / Sales 2024 * | 13.1 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 13.1 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 8 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Can-Fite BioPharma Ltd.
More press releases
| 1 week | +7.41% | ||
| Current month | +11.54% | ||
| 1 month | +11.54% | ||
| 3 months | +7.41% | ||
| Current year | +11.54% |
1 week
2.60
3.00
1 month
2.603.00
Current year
2.503.00
1 year
2.504.10
3 years
2.1031.10
5 years
2.1052.80
10 years
2.101 163.00
| Managers | Title | Age | Since |
|---|---|---|---|
Motti Farbstein
CEO | Chief Executive Officer | 59 | 31/07/03 |
Pnina Fishman
FOU | Founder | 74 | 10/09/94 |
Ilan Cohn
FOU | Founder | 68 | 10/09/94 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Abraham Sartani
BRD | Director/Board Member | 76 | 31/12/00 |
Ilan Cohn
FOU | Founder | 68 | 10/09/94 |
Pnina Fishman
FOU | Founder | 74 | 10/09/94 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/05/24 | 2.9 | 0.00% | 570 338 |
| 20/05/24 | 2.9 | 0.00% | 8,177,351 |
| 19/05/24 | 2.9 | +11.54% | 7,665,227 |
| 16/05/24 | 2.6 | -3.70% | 4,787,270 |
| 15/05/24 | 2.7 | 0.00% | 9,676,994 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 21, 2024 at 10:37 am
More quotes
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Sector
Pharmaceuticals
Calendar
29/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.029
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.54% | 11.79M | |
| -3.15% | 89.69B | |
| +3.95% | 41.34B | |
| -10.51% | 33.72B | |
| +59.06% | 26.11B | |
| -20.09% | 14.63B | |
| -8.92% | 12.84B | |
| -11.46% | 11.66B | |
| -43.05% | 11.52B | |
| +4.64% | 8.92B |
- Stock Market
- Equities
- CANF Stock
